• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

替代治疗外显子跳跃修复杜氏肌营养不良症的实验和计算比较。

Empirical and Computational Comparison of Alternative Therapeutic Exon Skip Repairs for Duchenne Muscular Dystrophy.

出版信息

Biochemistry. 2019 Apr 16;58(15):2061-2076. doi: 10.1021/acs.biochem.9b00062. Epub 2019 Apr 1.

DOI:10.1021/acs.biochem.9b00062
PMID:30896926
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6583923/
Abstract

Duchenne muscular dystrophy (DMD) is a common and devastating genetic disease primarily caused by exon deletions that create a genetic frameshift in dystrophin. Exon skipping therapy seeks to correct this by masking an exon during the mRNA maturation process, restoring dystrophin expression, but creating an edited protein missing both the original defect and the therapeutically skipped region. Crucially, it is possible to correct many defects in alternative ways, by skipping an exon either before or after the patient's defect. This results in alternatively edited, hybrid proteins that might have different properties and therapeutic consequences. We examined three such dystrophin exon-skipped edits, Δe45-53, Δe46-54, and Δe47-55, comprising two pairs of alternative repairs of Δe46-53 and Δe47-54 DMD defects. We found that in both cases, Δe46-54 was the more stable repair as determined by a variety of thermodynamic and biochemical measurements. We also examined the origin of these differences with molecular dynamics simulations, which showed that these stability differences were the result of different types of structural perturbations. For example, in one edit there was partial unfolding at the edit site that caused domain-localized perturbations while in another there was unfolding at the protein domain junctions distal to the edit site that increased molecular flexibility. These results demonstrate that alternative exon skip repairs of the same underlying defect can have very different consequences at the level of protein structure and stability and furthermore that these can arise by different mechanisms, either locally or by more subtle long-range perturbations.

摘要

杜氏肌营养不良症(DMD)是一种常见且严重的遗传性疾病,主要由外显子缺失引起,导致肌营养不良蛋白发生遗传移码。外显子跳跃疗法试图通过在 mRNA 成熟过程中掩盖外显子来纠正这种情况,从而恢复肌营养不良蛋白的表达,但会产生一种编辑后的蛋白,既缺失原始缺陷,又缺失治疗性跳跃区域。至关重要的是,通过在患者缺陷之前或之后跳过外显子,可以以多种替代方式纠正许多缺陷。这会产生具有不同性质和治疗后果的替代性编辑的混合蛋白。我们研究了三种肌营养不良蛋白外显子跳跃编辑,Δe45-53、Δe46-54 和 Δe47-55,它们包含对 Δe46-53 和 Δe47-54 DMD 缺陷的两种替代性修复的两对。我们发现,通过各种热力学和生化测量,在这两种情况下,Δe46-54 都是更稳定的修复。我们还通过分子动力学模拟研究了这些差异的起源,结果表明这些稳定性差异是由于不同类型的结构扰动造成的。例如,在一种编辑中,编辑部位发生部分展开,导致结构域局部扰动,而在另一种编辑中,编辑部位远端的蛋白质结构域连接处发生展开,增加了分子的灵活性。这些结果表明,同一潜在缺陷的替代性外显子跳跃修复在蛋白质结构和稳定性水平上可能具有非常不同的后果,并且这些后果可能是由不同的机制引起的,要么是局部的,要么是更微妙的远程扰动。

相似文献

1
Empirical and Computational Comparison of Alternative Therapeutic Exon Skip Repairs for Duchenne Muscular Dystrophy.替代治疗外显子跳跃修复杜氏肌营养不良症的实验和计算比较。
Biochemistry. 2019 Apr 16;58(15):2061-2076. doi: 10.1021/acs.biochem.9b00062. Epub 2019 Apr 1.
2
Structural Perturbations of Exon-Skipping Edits within the Dystrophin D20:24 Region.外显子跳跃编辑的肌营养不良蛋白 D20:24 区结构扰动。
Biochemistry. 2021 Mar 16;60(10):765-779. doi: 10.1021/acs.biochem.0c00827. Epub 2021 Mar 3.
3
Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.靶向外显子跳跃作为杜氏肌营养不良症的一种潜在基因校正疗法。
Neuromuscul Disord. 2002 Oct;12 Suppl 1:S71-7. doi: 10.1016/s0960-8966(02)00086-x.
4
Differential stabilities of alternative exon-skipped rod motifs of dystrophin.肌营养不良蛋白替代外显子跳跃杆状基序的差异稳定性
Biochim Biophys Acta. 2009 Jun;1794(6):921-8. doi: 10.1016/j.bbapap.2009.02.016. Epub 2009 Mar 12.
5
Exon-skipped dystrophins for treatment of Duchenne muscular dystrophy: mass spectrometry mapping of most exons and cooperative domain designs based on single molecule mechanics.外显子跳跃肌营养不良蛋白治疗杜氏肌营养不良症:基于单分子力学的大多数外显子和协同结构域设计的质谱映射。
Cytoskeleton (Hoboken). 2010 Dec;67(12):796-807. doi: 10.1002/cm.20489. Epub 2010 Nov 10.
6
Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.定量反义筛选和优化用于杜氏肌营养不良症外显子 51 跳跃。
Mol Ther. 2017 Nov 1;25(11):2561-2572. doi: 10.1016/j.ymthe.2017.07.014. Epub 2017 Jul 28.
7
Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide Approach.利用反义寡核苷酸方法高效剔除 DMD 患者来源细胞系中的单外显子重复。
J Neuromuscul Dis. 2017;4(3):199-207. doi: 10.3233/JND-170233.
8
In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.反义磷酰二胺吗啉代寡聚物(PMO)在营养不良犬和7号外显子缺失的杜氏肌营养不良症(DMD)患者中诱导的体外多外显子跳跃
Methods Mol Biol. 2018;1828:151-163. doi: 10.1007/978-1-4939-8651-4_9.
9
Designing Effective Antisense Oligonucleotides for Exon Skipping.设计用于外显子跳跃的有效反义寡核苷酸
Methods Mol Biol. 2018;1687:143-155. doi: 10.1007/978-1-4939-7374-3_10.
10
Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.在杜氏肌营养不良症的mdx52小鼠模型中使用磷酰二胺吗啉代寡聚物进行外显子跳跃疗法
Methods Mol Biol. 2018;1687:123-141. doi: 10.1007/978-1-4939-7374-3_9.

引用本文的文献

1
Advances in Genetic Characterization and Genotype-Phenotype Correlation of Duchenne and Becker Muscular Dystrophy in the Personalized Medicine Era.个性化医疗时代杜兴氏和贝克氏肌肉营养不良症的基因特征及基因型-表型相关性研究进展
J Pers Med. 2020 Sep 3;10(3):111. doi: 10.3390/jpm10030111.

本文引用的文献

1
Dystrophin As a Molecular Shock Absorber.肌营养不良蛋白作为分子减震器。
ACS Nano. 2018 Dec 26;12(12):12140-12148. doi: 10.1021/acsnano.8b05721. Epub 2018 Nov 27.
2
Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.给予反义寡核苷酸 NS-065/NCNP-01 全身性治疗以跳过杜氏肌营养不良症患者的外显子 53。
Sci Transl Med. 2018 Apr 18;10(437). doi: 10.1126/scitranslmed.aan0713.
3
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.
杜氏肌营养不良症的诊断和管理,第 1 部分:诊断和神经肌肉、康复、内分泌、胃肠和营养管理。
Lancet Neurol. 2018 Mar;17(3):251-267. doi: 10.1016/S1474-4422(18)30024-3. Epub 2018 Feb 3.
4
Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues.《Duchenne 肌营养不良症外显子跳跃疗法的发展:批判性评价及对突出问题的展望》
Nucleic Acid Ther. 2017 Oct;27(5):251-259. doi: 10.1089/nat.2017.0682. Epub 2017 Aug 10.
5
Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six-Minute Walk Test.利用六分钟步行试验建立杜氏肌营养不良自然病史进展模型
CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):596-603. doi: 10.1002/psp4.12220. Epub 2017 Aug 29.
6
Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy.迈向杜氏肌营养不良症成功的外显子跳跃治疗。
J Hum Genet. 2017 Oct;62(10):871-876. doi: 10.1038/jhg.2017.57. Epub 2017 Jun 1.
7
A rare subclinical or mild type of Becker muscular dystrophy caused by a single exon 48 deletion of the dystrophin gene.一种由肌营养不良蛋白基因第48外显子单缺失引起的罕见的亚临床型或轻型贝克肌营养不良症。
J Appl Genet. 2017 Aug;58(3):343-347. doi: 10.1007/s13353-017-0391-8. Epub 2017 Feb 28.
8
Exon skipping: a first in class strategy for Duchenne muscular dystrophy.外显子跳跃:杜氏肌营养不良症的首创治疗策略
Expert Opin Biol Ther. 2017 Feb;17(2):225-236. doi: 10.1080/14712598.2017.1271872. Epub 2016 Dec 23.
9
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga.美国食品药品监督管理局批准依特普肽用于治疗杜氏肌营养不良症:依特普肽传奇的新篇章。
Nucleic Acid Ther. 2017 Feb;27(1):1-3. doi: 10.1089/nat.2016.0657. Epub 2016 Dec 8.
10
The Structure of the Plakin Domain of Plectin Reveals an Extended Rod-like Shape.网蛋白的片层蛋白结构域呈现出一种细长的杆状形态。
J Biol Chem. 2016 Sep 2;291(36):18643-62. doi: 10.1074/jbc.M116.732909. Epub 2016 Jul 13.